4.7 Review

Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches

期刊

JOURNAL OF MOLECULAR BIOLOGY
卷 434, 期 3, 页码 -

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2021.167221

关键词

iPSCs; genetic diversity; ancestry; therapeutics; sex

资金

  1. Stanley Center for Psychiatric Research atthe Broad Institute, the Brain and Behavior Research Foundation (NARSAD younginvestigator award), [5U01MH115727]
  2. National Institute of Health (NIH/NIMH)

向作者/读者索取更多资源

Since the discovery of human pluripotent stem cell (hPSC) technologies, they have rapidly expanded beyond investigative research to drug discovery and development. However, there are still limitations to the utility of hPSC models. This review highlights the importance of diversifying hPSC collections, selecting therapeutically relevant models, increasing the scale of cell-based studies, and understanding genetic biases and the impact of sex and ancestry. The next decade of hPSC innovation is expected to provide vast insights into human disease and develop safe therapies for diverse populations.
Since their discovery 15 years ago, human pluripotent stem cell (hPSC) technologies have begun to revolutionize science and medicine, rapidly expanding beyond investigative research to drug discovery and development. Efforts to leverage hPSCs over the last decade have focused on increasing both the complexity and in vivo fidelity of human cellular models through enhanced differentiation methods. While these evolutions have fostered novel insights into disease mechanisms and influenced clinical drug discovery and development, there are still several considerations that limit the utility of hPSC models. In this review, we highlight important, yet underexplored avenues to broaden their reach. We focus on (i) the importance of diversifying existing hPSC collections, and their utilization to investigate therapeutic strategies in individuals from different genetic backgrounds, ancestry and sex; (ii) considerations for the selection of therapeutically relevant hPSC-based models; (iii) strategies to adequately increase the scale of cell-based studies; and (iv) the advances and constraints of clinical trials in a dish. Moreover, we advocate for harnessing the translational capabilities of hPSC models along with the use of innovative, scalable approaches for understanding genetic biases and the impact of sex and ancestry on disease mechanisms and drug efficacy and response. The next decade of hPSC innovation is poised to provide vast insights into the genetic basis of human disease and enable rapid advances to develop, repurpose, and ensure the safety of the next generation of disease therapies across diverse human populations.(c) 2021 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据